PDF
(Download)
|
- Turmeric (Curcuma longa)
- Boswellia (Indian Frankincense; Boswellia serrata)
- Knee Osteoarthritis
|
Date:
10-31-2013 | HC# 101361-483
|
Re: Turmeric and Boswellia Combination Reduces Knee Osteoarthritis Symptoms More Effectively than Celecoxib
Kizhakkedath
R. Clinical evaluation of a formulation containing Curcuma longa and Boswellia
serrata extracts in the management of knee osteoarthritis. Mol Med Rep. November 2013;8(5):1542-1548.
The
degenerative joint disease osteoarthritis (OA) is physically debilitating and
significantly impairs quality of life. As the cause of OA remains unknown, current
medical treatment is directed towards alleviating pain and restoring movement using
nonsteroidal anti-inflammatory drugs (NSAIDs). However, long term use of NSAIDs
is associated with significantly increased risk of gastrointestinal, renal, and
cardiovascular adverse effects. Turmeric (Curcuma
longa) rhizome has been shown to have both anti-inflammatory and antioxidant
activity. In clinical trials, boswellia (Indian frankincense; Boswellia serrata) gum resin has shown positive
effects in treating both rheumatoid arthritis and OA. This randomized,
observational trial tested the efficacy of a turmeric and boswellia (CB) combination
in comparison to celecoxib (a standard NSAID) in alleviating the symptoms of
knee OA.
The
CB combination consisted of 350 mg of turmeric extract standardized to contain
70% curcumin, 17% demethoxycurcumin, 3.5% bisdemethoxycurcumin, and 7.5%
turmeric essential oils, and 150 mg boswellia extract consisting of 75%
boswellic acids and 10% 3-O-acetyl-11-keto-boswellic acid (AKBA). Although the
turmeric constituent curcumin has been shown to have significant anti-inflammatory
activity, oral bioavailability is very poor. A formulation providing improved
curcumin bioavailability was used in this study. And while the boswellia
constituent AKBA also has significant anti-inflammatory activity, the authors
point out that most commercial boswellia extracts contain a relatively low
concentration of AKBA (~2%). The boswellia extract used in this study was
"enhanced" to contain 10% AKBA. The CB combination was provided in
500 mg capsules produced by Arjuna Natural Extracts Ltd.; Aluva, Kerala, India.
No other information on the proprietary formula was provided.
In
this 12-week study, conducted at Anugraha Medical Centre in Kochi, Kerala, India,
30 patients with OA were randomly assigned to receive either 500 mg of CB twice
daily or 100 mg of celecoxib 2 times per day. The study included 8 clinic
visits where vital signs, OA symptom scores, and physical exam results were recorded.
Included patients were men and women between 18-65 years old diagnosed with moderate
OA based upon radiographic evidence. Those with gross OA deformity, severe OA, severe
swelling and restricted mobility, rheumatoid or reactive arthritis, other systemic
diseases, malnutrition, history of alcohol or drug abuse, and breastfeeding
women were excluded.
The
OA symptoms scored were joint pain (no pain, mild, moderate, or severe),
walking distance (greater than 1,000 m, 500-1,000 m, 100-500 m, or less than
100 m), joint tenderness (no tenderness, improved, same, or worsened), and
crepitus or crackling sounds (no crepitus, mild, moderate, or severe). Knee swelling
and thigh circumference were quantified using a measuring tape and range of
movement was assessed in degrees using a goniometer. Joint warmth (yes, no) and
gait (normal or abnormal) were also assessed. To evaluate safety, vital signs, hemogram
(laboratory blood parameters), and liver and kidney function were measured at
baseline, 6 weeks, and 12 weeks. The authors did not indicate whether they
queried patients about possible adverse effects.
In
total, 28 patients finished the study, with 1 patient from each group dropping
out due to personal reasons or uncontrolled symptoms. At baseline, no significant
differences were observed in age, height, weight, body mass index (BMI),
temperature, blood pressure, pulse rate, or respiration between the groups.
Although pain severity significantly improved from baseline to endpoint
(P<0.05) in both groups, no significant differences between groups were
observed. However, the number of patients improved was markedly higher in the
treatment group; 85.71% of patients were classified in the moderate/severe
range at baseline, and at endpoint, only 21.43% of patients were in this
category. In the control group, 78.57% of the patients had moderate/severe pain
at baseline and 50% still had moderate/severe pain at the endpoint.
Improvement
in walking distance was seen in both groups (P<0.05), with 92.86% of those
in the treatment group and 85.71% of those in the control group able to walk
more than 1000 m at endpoint; however, there were no significant differences
between groups. Also, both groups had significantly less joint tenderness at
the end of the study (P<0.05). In the treatment group, 85.71% had
moderate/severe joint tenderness at baseline, and this decreased to 7.14% of
patients at the end of the study. Patients in the control group showed a
smaller improvement in joint tenderness, declining from 78.57% at baseline to
21.43% of patients after 12 weeks of treatment. Crepitus improved in both
groups from baseline to endpoint (P<0.05); there was also a significant
beneficial effect seen in range of movement (P<0.05) in both groups.
Swelling, joint warmth, gait, and thigh measurements were not changed in either
group. Vital signs, blood parameters, and liver and kidney function remained
unchanged. No adverse effects were reported in either group.
The
authors conclude that improvements in pain severity, walking distance, and
joint tenderness were superior in those taking the CB supplement compared to
the NSAID control medication and that CB was comparable to celecoxib in increasing
range of movement and decreasing crepitus. They state, "The efficacy and
tolerability of [the] CB formulation used in the current study was shown to be
superior to those of celecoxib (NSAID) for treating active OA."
The
authors hypothesized that the CB formulation would be as effective as celecoxib
in reducing OA symptoms, and cause fewer adverse effects. While the effectiveness
of the 2 treatments appeared to be comparable, no adverse effects were reported
in either group. Studies with a larger sample size are needed to confirm the
efficacy of CB and to detect differences in the occurrence rate of adverse
effects.
—Amy C. Keller,
PhD
|